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Zopiclone misuse on a methadone
maintenance programme
This study highlights the prevalence of zopiclonemisuse in clients attending a methadonemaintenance programme in Dublin through
detection of its degradation product, 2-amino-5-
chloropyridine (ACP) on urinalysis. Urine samples from
all 158 clients were tested for the presence of ACP, opiates,
benzodiazepines, cocaine, alcohol and cannabis. Of the 37
(23%) clients who tested positive for ACP, 23 (62%) were
interviewed and details regarding their demographics,
drug history, viral status, recent urinalysis results and
opinions on zopiclone were collected. Of the 14 (38%)
clients who were not interviewed, information was
obtained from their case notes and urinalysis results.
A description of zopiclone misusers is outlined. The
prevalence of zopiclone misuse is 23%. Re-testing at four to
five months indicates a persistence of zopiclone misuse of
17%. Benzodiazepines were the most popular drug of misuse
with zopiclone followed by heroin/opiates. Zopiclone is
being misused by drug users in the context of many other
drugs and prescribing it in primary and secondary care
should be restricted, especially among drug users.
INTRODUCTION
Zopiclone was initially introduced in 1987 for the treatment
of insomnia.1 It is a cyclopyrolone, chemically unrelated to
benzodiazepines and acts on the gamma-aminobutyric acid
(GABA)-A receptor complex, potentiating neuronal.2 It has a
half life of five hours (up to eight hours in the elderly).1 The
drug was marketed as a safe and non-addictive
hypnosedative and, as such, was less likely to cause
dependence, withdrawal symptoms or rebound
phenomena.1-5 It is commonly prescribed in the management
of insomnia in primary care and general hospital settings. 
Chronic use of either benzodiazepines or alcohol may
cause some receptor modification at the GABA receptor
which may lead to cross-tolerance with zopiclone.2,6 These
changes may be significant in the pathophysiology of
tolerance and withdrawal states and may explain the altered
sensitivity to the subsequent administration of either of
these drugs.2,7 There appears to be a cross-tolerance between
benzodiazepines and zopiclone and transference of misuse
from a benzodiazepine to zopiclone has been previously
documented.1 Studies suggest that patients can be readily
weaned off long-term benzodiazepines through an
intermediate stage of zopiclone prescribing.8-10
There are well-documented case reports of zopiclone
misuse, dependency, rebound insomnia and withdrawal
symptoms in opiate and polydrug users2,5,6,11-15 and in those
cases without co-morbid opiate misuse.2,11,13,16,17 These
problems have also been described in patients with anxiety
and dependent personalities.12 A withdrawal syndrome has
been recognised after high dose zopiclone misuse1,13,16,18-20 and
rebound insomnia occurring in normal volunteers after only
two to three weeks on zopiclone.1,13,21 Withdrawal seizures
following abrupt withdrawal of zopiclone have also been
described.22
Fatalities have been documented following ingestion of
zopiclone, one case involved a 72 year old man who was
being treated for lung cancer and died following an overdose
of zopiclone 90mg.23 Also two other deaths have been
described following ingestion of zopiclone.24 In 2001, the
National Poisons Information Centre in Ireland received 238
calls regarding zopiclone (total 11,401 calls to the centre)
which was the fourth most enquired about agent after
ethanol, paracetamol and Dalmane.25 To date, there have
been no reports of fatalities in Ireland relating to zopiclone
ingestion.26
AIM
The aim of this study was to assess the prevalence of
zopiclone misuse in all clients attending a methadone
maintenance programme through detection of its
degradation product, ACP, on urinalysis. A description of
clients who misuse zopiclone is outlined. Warnings
regarding the potential for zopiclone misuse or dependency
in clients receiving methadone from their primary care
physician or psychiatrist are highlighted.
METHODS
All clients (158) attending the methadone maintenance
programme were tested for the presence of ACP. Thirty-
seven (23%) samples tested positive for ACP, and so were
also tested for the presence of opiates, benzodiazepines,
methadone, cannabis, alcohol, tricyclic antidepressants and
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cocaine. Of this sample, 27 (17%) were re-tested for ACP
four to five months later. Ten clients were unable to submit
samples — three were in prison, five no longer attended the
clinic and two were on the harm minimisation programme.
All clients were supervised during urine sampling to reduce
the likelihood of bogus samples.
Of the 37 clients (17 male) who tested positive for ACP on
initial screening, 23 agreed to be interviewed by the
specialist registrar in psychiatry. Details regarding their
demographics, drug history, viral status, recent urinalysis
findings and personal views and experiences on zopiclone
were obtained. Fourteen (38%) clients were not interviewed:
six refused, three were in prison and five were no longer
attending the clinic. Of the 14 clients who were not
interviewed, information was obtained from their case notes
regarding the prescribing of zopiclone and documented
urinalysis results. Information was analysed using SPSS
Windows 8.0.
SAMPLE COLLECTION AND STORAGE
The sample preparation and analysis was based on a method
described by Galloway.27 Samples were deemed to be positive
for zopiclone on the basis of the detection of ACP in a
sample. Further details regarding this method of analysis
may be obtained from the author.
RESULTS
Thirty-seven (23%) clients from a total of 158 attending a
methadone maintenance day programme were positive for
the zopiclone metabolite, ACP. On re-testing four to five
months later, 27 (17%) of the total 158 clients remained
positive for ACP, and 23 of them were interviewed.
The mean age of the sample interviewed was 32 years. Six
(26%) were male, 17 (74%) were female, 16 (70%) were
single, 10 (44%) were living in rented accommodation and 4
(17%) were homeless. Although the majority of the sample
had had partial secondary school education, only 3 (13%)
had obtained the Intermediate/Junior certificate and the
Leaving certificate. One hundred per cent of the sample were
unemployed (see Table 1).
The mean age of the other 121 clients who tested negative
for zopiclone was 30.5 years (range 19-48 years); 95 (78.5%)
were male and 26 (21.5%) were female.
Of the sample interviewed, the mean ages of first drug use
and intravenous use was 14.5 years and 20.2 years,
respectively. The mean duration of intravenous drug use was
11.2 years. Almost all clients (22, 95%) had a history of
intravenous drug use and the prevalence of hepatitis C
infection was 74% (see Table 1). The overall prevalence rate
of hepatitis C among clients was 70%, and 98% of clients
had a history of intravenous drug use.
Of the 37 (23%) clients who tested positive for ACP on
initial screening, 16 (43%) also tested positive for opiates
and 24 (69.9%) tested positive for benzodiazepines at that
time. All clients had a past history of opiate misuse.
Of the 23 clients interviewed, all had a history of opiate,
benzodiazepine and cannabis misuse with a mean duration of
misuse of 11.8 years, 10.1 years and 13.5 years, respectively.
Nineteen clients (82%) had a history of alcohol and ecstasy
misuse with a mean duration of misuse of 15.6 years and 4.5
years, respectively. The most popular current drugs of misuse
were benzodiazepines, followed by heroin, which is evident
from the first urinalysis results, whereby 23 (100%) tested
positive for benzodiazepines and 14 (61%) tested positive for
heroin. Although alcohol was admitted to be a current drug of
use, it was not identified on urinalysis. Cocaine was identified
in 14 clients (61%) on first urinalysis testing. The findings of
the second urinalysis indicate a reduction in the use of heroin,
benzodiazepines and cocaine; however, benzodiazepines
remain the most popular drug of misuse.
Although zopiclone was prescribed for eight clients, with
three claiming they were taking it as prescribed, urinalysis
results did not provide information on the level or pattern of
Table 1. Sociodemographic and clinical characteristics of sample
interviewed (n=23)
Age Mean (SD) 32 (5.6)
(years) Range 22-43
Gender Female 17 (74%)
Marital status Single 16 (70%)
Co-habiting 6 (26%)
Widowed 1 (4%)
Living with Alone 4 (17%)
Partner/children 4 (17%)
Family of origin 9 (39%)
Accommodation Family home 8 (34%)
Rented 10 (44%)
Homeless 4 (17%)
Employment status Unemployed 23 (100%)
Education Partial primary 3 (13%)
Partial Secondary 19 (83%)
Partial third level 1 (4%)
Examinations Junior/Intermediate 3 (13%)
certificate
Leaving certificate 3 (13%)
Age (years)
1st drug use Mean (SD) 14.5 (3.6)
Range 11-27 
1st IV drug use Mean (SD) 20.3 (6.1)
Range 14-36
Duration of IV drug Mean (SD) 11.2 (6.2)
use (years) Range 2-23  
Viral status Hepatitis C positive 17 (74%)
Hepatitis B positive 2 (9%)
HIV positive 2 (9%)
SD=standard deviation
First admission: 5 (11%)
Re-admissions: 40 (89%)
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use. The mean age of first use of zopiclone was 28 years and
the mean duration of use was 4.2 years. The mean dose
taken was 50.2mg (range 15-300mg) with 12 (52%) of the
sample taking zopiclone daily. No client had injected
zopiclone (see Table 3).
DISCUSSION
The literature is quite limited regarding the misuse of
zopiclone. Although abuse and dependence following long-
term use can occur, it is rare considering the world-wide
extent of usage.1,4-5,28-30 Large studies have been conducted
with zopiclone in the UK19 (n=13,177) and in Spain31
(n=3,605); however, the authors did not report any
problems after stopping medication in normal doses.19,31 A
meta-analysis32 and a review3 of sleep laboratory studies
reported that tolerance, rebound and withdrawal
phenomena were marginal and mild, nevertheless, long-
term, controlled, prospective studies are awaited to address
this issue. A recent review of 22 case studies, revealed that
reporting of zopiclone abuse or dependence is rare, and
concluded that zopiclone is a relatively safe drug.5
Nevertheless, there have been warnings about the drug’s
misuse.14,33 The risk of dependency and abuse is greater in
alcohol misuers,34 polysubstance misusers,1,2,5-6,18,35 clients
who have dependent personalities12,36 or other psychiatric
disorders.5,34-36 All clients in primary and secondary care,
with or without a positive psychiatric history, are at risk of
zopiclone misuse or dependency. A recent post-marketing
study suggests that the risk of misuse of zopiclone is less
than that of benzodiazepines, and similar to that of sedating
antidepressants.37 Worryingly, similar problems have also
been reported in non-drug users.2,12,13,16,17
Results from this study indicate a high level of zopiclone
misuse (23% of 158 clients on a methadone maintenance
programme). Re-testing at four to five months indicates a
persistence of zopiclone misuse as 17% continue to test
positive for the zopiclone metabolite, ACP. Zopiclone misusers
tend to be marginally older, female, single and unemployed
with a long duration of polydrug use. The majority have
injected other drugs, and the prevalence of hepatitis C is 74%.
All the sample interviewed have a past history of heroin,
benzodiazepine and cannabis use, with 82-86% also having a
history of alcohol, ecstasy, LSD, amphetamines and cocaine
use. Benzodiazepines appear to be the most popular drug of
misuse with zopiclone, followed by heroin/opiates, cocaine
and cannabis as documented on first urinalysis. On the second
urinalysis, zopiclone and benzodiazepines continue to remain
the most popular drugs of misuse.
The mean daily dose of zopiclone (50.2mg) was lower
than a daily average dose of 105mg (range 90-380mg)
reported in the literature, but the duration of misuse in this
study (4.2 years) is longer than the previous report of 10
months.9 Interestingly, a maximum daily dose of 300mg was
recorded in this clinic compared to a maximum daily dose of
150mg reported in the literature.15 Although there were no
fatalities, there is a potential risk of fatalities in the future in
view of the high doses currently being ingested. Following
the death of a 72 year old man from an overdose of 75mg of
zopiclone, Meatherall outlined that 75mg may represent a
minimum lethal dose of zopiclone.24
Table 2. Past and current drug use of the clients interviewed (n=23)
Past drug use Mean duration of abuse Current drug use 1st urinalysis 2nd urinalysis 
(as per interview) (years) (as per interview) (4-5 months later)
Heroin/opiates 23 (100%) 11.8 12 (53%) 14 (61%) 9 (39%)
Benzodiazepines 23 (100%) 10.1 16 (70%) 23 (100%) 15 (65%)
Cocaine 19 (82%) 5.0 4 (17%) 14 (61%) 1 (4%)
Alcohol 19 (82%) 15.6 17 (46%) 0 0
Ecstasy 19 (82%) 4.5 1 (2.7%) 3 (13%) 0
LSD 20 (86%) 5 * * *
Amphetamines 20 (86%) 5.3 * * *
Cannabis 23 (100%) 13.5 17 (46%) 12 (52%) 13 (56.5%)
*Analysis not routinely performed
Table 3. Zopiclone misuse (n=23)
Dose (mg) Mean dose 50.2
range 15-300
Age of first use (years) Mean (SD) 28 (7.2)
Range 16-40
Duration of misuse (years) Mean (SD) 4.2 (3.1)
Range 1-10
Frequency of misuse Daily 12 (52%)
2-4 occasions/week 3 (13%)
Once-weekly 2 (8.7%)
SD=standard deviation
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All clients are misusers of benzodiazepines and prefer
zopiclone because it does not cause amnesia to the same extent
as the benzodiazepines. They like it, and report that it
potentiates their experience on heroin and promotes a feeling
of sedation and tranquilisation that is desired. Although
zopiclone is only available with a prescription, clients claim
that it is easily bought on the streets in Ireland, is cheap and
readily prescribed by doctors in primary and secondary care.
Our findings are similar to trends in other clinics and concur
with real concerns that have been expressed regarding the
abuse potential of zopiclone.1,2,4-6,12,14,22,38-40
However, while follow up urinalysis and interviews were
carried out on 27 (73%) and 23 (62%) clients, respectively, it
is important to note that this may not be totally representative
of the overall population who were using zopiclone. 
CONCLUSION
Zopiclone, which has been known as a ‘safe and non-
addictive’ substitute for benzodiazepines, is clearly being
misused by drug users in the context of other drugs
(primarily benzodiazepines and heroin/opiates). All clients,
even those without a psychiatric history, are at risk of
developing zopiclone misuse or dependency. As
prescriptions for zopiclone are easily obtained from doctors
in most specialties, there is a need for greater restrictions in
prescribing this drug to known drug users because of its
potential for misuse and dependency. Care should be taken
when prescribing zopiclone in primary and secondary care,
even if there is no history of substance misuse.
Similar advice should be given to patients when
commencing Zopiclone as would be given when prescribing
benzodiazepines. As with all drugs in this class, short-term
prescribing with careful monitoring is essential. Further
evaluation research is necessary to determine the potential
for misuse and dependence of zopiclone.
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